Kerrisdale’s Sahm Adrangi leads a brutal new biotech short attack as trial results loom
Kerrisdale Capital’s Sahm Adrangi has called a couple of recent biotech disasters in advance. Just two months ago his prediction that Bavarian Nordic’s cancer vaccine would flunk a long-running study proved accurate, and that came right on the heels of Sage’s ugly misfire on SRSE demonstrating that the drug was no better than a placebo in getting a response.
Now the influential hedge fund manager has got a new biotech in his sights, and this morning he’s pulling the trigger on another short attack, blasting the company’s lead drug as an absolute failure in the making.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
